TY - JOUR
T1 - An international perspective on hospitalized patients with viral community-acquired pneumonia
AU - GLIMP Investigators
AU - Radovanovic, Dejan
AU - Sotgiu, Giovanni
AU - Jankovic, Mateja
AU - Mahesh, Padukudru Anand
AU - Marcos, Pedro Jorge
AU - Abdalla, Mohamed I.
AU - Di Pasquale, Marta Francesca
AU - Gramegna, Andrea
AU - Terraneo, Silvia
AU - Blasi, Francesco
AU - Santus, Pierachille
AU - Aliberti, Stefano
AU - Reyes, Luis F.
AU - Restrepo, Marcos I.
AU - Aruj, Patricia Karina
AU - Attorri, Silvia
AU - Barimboim, Enrique
AU - Caeiro, Juan Pablo
AU - Garzón, María I.
AU - Cambursano, Victor Hugo
AU - Ceccato, Adrian
AU - Chertcoff, Julio
AU - Cordon Díaz, Ariel
AU - de Vedia, Lautaro
AU - Ganaha, Maria Cristina
AU - Lambert, Sandra
AU - Lopardo, Gustavo
AU - Luna, Carlos M.
AU - Malberti, Alessio Gerardo
AU - Morcillo, Nora
AU - Tartara, Silvina
AU - Pensotti, Claudia
AU - Pereyra, Betiana
AU - Scapellato, Pablo Gustavo
AU - Stagnaro, Juan Pablo
AU - Shah, Sonali
AU - Lötsch, Felix
AU - Thalhammer, Florian
AU - Anseeuw, Kurt
AU - Francois, Camille A.
AU - Van Braeckel, Eva
AU - Vincent, Jean Louis
AU - Djimon, Marcel Zannou
AU - Aranha Nouér, Simone
AU - Chipev, Peter
AU - Encheva, Milena
AU - Miteva, Darina
AU - Petkova, Diana
AU - Dalhoff, Klaus
AU - Rupp, Jan
PY - 2018
Y1 - 2018
N2 - Background: Who should be tested for viruses in patients with community acquired pneumonia (CAP), prevalence and risk factors for viral CAP are still debated. We evaluated the frequency of viral testing, virus prevalence, risk factors and treatment coverage with oseltamivir in patients admitted for CAP. Methods: Secondary analysis of GLIMP, an international, multicenter, point-prevalence study of hospitalized adults with CAP. Testing frequency, prevalence of viral CAP and treatment with oseltamivir were assessed among patients who underwent a viral swab. Univariate and multivariate analysis was used to evaluate risk factors. Results: 553 (14.9%) patients with CAP underwent nasal swab. Viral CAP was diagnosed in 157 (28.4%) patients. Influenza virus was isolated in 80.9% of cases. Testing frequency and viral CAP prevalence were inhomogeneous across the participating centers. Obesity (OR 1.59, 95%CI: 1.01–2.48; p = 0.043) and need for invasive mechanical ventilation (OR 1.62, 95%CI: 1.02–2.56; p = 0.040) were independently associated with viral CAP. Prevalence of empirical treatment with oseltamivir was 5.1%. Conclusion: In an international scenario, testing frequency for viruses in CAP is very low. The most common cause of viral CAP is Influenza virus. Obesity and need for invasive ventilation represent independent risk factors for viral CAP. Adherence to recommendations for treatment with oseltamivir is poor.
AB - Background: Who should be tested for viruses in patients with community acquired pneumonia (CAP), prevalence and risk factors for viral CAP are still debated. We evaluated the frequency of viral testing, virus prevalence, risk factors and treatment coverage with oseltamivir in patients admitted for CAP. Methods: Secondary analysis of GLIMP, an international, multicenter, point-prevalence study of hospitalized adults with CAP. Testing frequency, prevalence of viral CAP and treatment with oseltamivir were assessed among patients who underwent a viral swab. Univariate and multivariate analysis was used to evaluate risk factors. Results: 553 (14.9%) patients with CAP underwent nasal swab. Viral CAP was diagnosed in 157 (28.4%) patients. Influenza virus was isolated in 80.9% of cases. Testing frequency and viral CAP prevalence were inhomogeneous across the participating centers. Obesity (OR 1.59, 95%CI: 1.01–2.48; p = 0.043) and need for invasive mechanical ventilation (OR 1.62, 95%CI: 1.02–2.56; p = 0.040) were independently associated with viral CAP. Prevalence of empirical treatment with oseltamivir was 5.1%. Conclusion: In an international scenario, testing frequency for viruses in CAP is very low. The most common cause of viral CAP is Influenza virus. Obesity and need for invasive ventilation represent independent risk factors for viral CAP. Adherence to recommendations for treatment with oseltamivir is poor.
UR - http://www.scopus.com/inward/record.url?scp=85055913331&partnerID=8YFLogxK
U2 - 10.1016/j.ejim.2018.10.020
DO - 10.1016/j.ejim.2018.10.020
M3 - Journal articles
AN - SCOPUS:85055913331
SN - 0953-6205
JO - European Journal of Internal Medicine
JF - European Journal of Internal Medicine
ER -